Ottaviani Giulia, Targato Giada, Rupel Katia, Gobbo Margherita, Generali Daniele, Guglielmi Alessandra, Dicorato Angela, Adamo Daniela, Canfora Federica, Di Lenarda Roberto, Biasotto Matteo
Department of Medical, Surgical and Health Sciences, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
Department od Medicine (DAME), University of Udine, 33100 Udine, Italy.
Cancers (Basel). 2023 Dec 29;16(1):176. doi: 10.3390/cancers16010176.
Oral problems in a group of oncological patients undergoing chemotherapy (CT) for solid tumors have been examined. Incidence and severity of patients' self-reported oral problems have been evaluated along their interaction with age, gender, tumor diagnosis and stage, presence of mestastasis, CT agent type, and number of CT cycle. We also analyzed the presence of paraesthesia and anaesthesia and their predisposing factors associated with clinical and treatment-related variables.
Patients were asked to fill in a questionnaire to evaluate the onset and the intensity of oral and perioral pain, oral mucositis, salivary gland hypofunction, dysgeusia, dysphagia, dysphonia, and sensitivity neuropathy (paraesthesia or dysaesthesia) since the last CT infusion. We also investigated which types of medications have possibly been used and who recommended it, as well as patients' degree of awareness about the possibility of oral problems arising during CT.
We recruited 194 patients and obtained 491 questionnaires. We found that a metastatic disease was a risk factor for OM (OR 2.02, = 0.026) and salivary gland hypofunction (OR 1.66, = 0.042) and that platinum agents, compared to mitotic inhibitors, increased the risk of developing salivary gland hypofunction (OR 2.16, = 0.013), dysphagia (OR 3.26, = 0.001), and anaesthesia (OR 5.16, = 0.041). Young age was a slight protective factor for most symptoms. The 80% of enrolled patients were informed by the oncologist about possible oral problems arising during CT.
Our study highlighted the importance of collecting observational data from the patients' perspective on oral problems arising during the routine oncology practice, across a range of solid tumors and CT regimens. The relevance of these findings focused on the key role of the multidisciplinary team in advising the patients on the possible occurrence of oral problems, also by recommending their management.
对一组接受实体瘤化疗(CT)的肿瘤患者的口腔问题进行了检查。评估了患者自我报告的口腔问题的发生率和严重程度,并分析了其与年龄、性别、肿瘤诊断和分期、转移情况、CT药物类型以及CT周期数之间的关系。我们还分析了感觉异常和麻木的存在情况及其与临床和治疗相关变量相关的诱发因素。
要求患者填写一份问卷,以评估自上次CT输注以来口腔和口周疼痛、口腔黏膜炎、唾液腺功能减退、味觉障碍、吞咽困难、发声困难以及感觉神经病变(感觉异常或感觉迟钝)的发作情况和强度。我们还调查了可能使用过哪些类型的药物以及是谁推荐使用的,以及患者对CT期间出现口腔问题可能性的知晓程度。
我们招募了194名患者,共获得491份问卷。我们发现转移性疾病是口腔黏膜炎(比值比[OR]2.02,P = 0.026)和唾液腺功能减退(OR 1.66,P = 0.042)的危险因素,并且与有丝分裂抑制剂相比,铂类药物会增加发生唾液腺功能减退(OR 2.16,P = 0.013)、吞咽困难(OR 3.26,P = 0.001)和麻木(OR 5.16,P = 0.041)的风险。年轻对大多数症状有轻微的保护作用。80%的入组患者从肿瘤学家那里得知了CT期间可能出现的口腔问题。
我们的研究强调了从患者角度收集关于常规肿瘤治疗实践中出现的口腔问题的观察数据的重要性,这些问题涵盖了一系列实体瘤和CT治疗方案。这些发现的相关性集中在多学科团队在就口腔问题的可能发生向患者提供建议方面的关键作用,包括推荐相应的处理措施。